# Best Peptides for IBD (Crohn's & Ulcerative Colitis): Evidence (2026)

> An evidence-first ranking of the peptides studied for inflammatory bowel disease — BPC-157, KPV, thymosin alpha-1 and larazotide acetate — separating decades of rodent colitis data from the near-total absence of human IBD trials.

*Published 2026-07-01 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
For inflammatory bowel disease specifically, **every peptide discussed here is preclinical (Grade C) at best** — the marketing narrative rests on rodent colitis models and cell culture, not human IBD trials. **No peptide has a completed, published, positive human RCT in Crohn's disease or ulcerative colitis**, and the most relevant gut-barrier peptide (larazotide) failed its pivotal Phase 3 trial. Guideline biologics and small molecules — not peptides — remain the standard of care.[1](https://peptidevox.com/#r1)[21](https://peptidevox.com/#r21)

This article is informational and editorial content for general education. It is **not medical advice, not a prescription or protocol to follow, and not a sourcing or buying guide**. IBD is a serious, relapsing-remitting immune-mediated disease that can cause strictures, fistulae, hospitalization, surgery and colorectal cancer; under-treatment carries real harm. Do not substitute, delay, taper or stop any prescribed IBD therapy to try a peptide — any decision must be made with, and monitored by, a board-certified gastroenterologist, including objective markers such as fecal calprotectin, CRP and endoscopy. Doses are reported strictly as seen in the published literature, never as guidance.

## How might peptides help in IBD, and what is the honest evidence bar?

IBD pathogenesis braids together three threads that peptides are theorized to target. First is **epithelial barrier dysfunction** — so-called leaky gut. Increased intestinal permeability is a documented, early feature of Crohn's disease, and zonulin, the endogenous tight-junction regulator, is elevated in both Crohn's and ulcerative colitis.[18](https://peptidevox.com/#r18) A leaky barrier lets luminal antigens and microbes reach the lamina propria and perpetuate inflammation. Second is **NF-κB–driven mucosal cytokine excess**: IBD mucosa over-produces TNF-α, IL-6, IL-1β, IFN-γ and IL-17 via NF-κB and MAP-kinase signaling.[7](https://peptidevox.com/#r7) Third is **loss of immune tolerance** — a failure of mucosal regulatory T-cell tone against the microbiota.[12](https://peptidevox.com/#r12)

The unifying theme — repair the barrier, dampen NF-κB, restore tolerance — is exactly the kind of upstream, root-cause logic that makes these peptides attractive from a functional/integrative view. The unresolved problem is that animal-to-human translation for gut-repair peptides has historically been poor, and the one barrier peptide taken to a pivotal human trial failed.[21](https://peptidevox.com/#r21) "Biologically plausible and promising in mice" is not "proven in patients." Throughout this review we separate human trials from preclinical models from anecdote, and we grade honestly: no peptide earns better than **Grade C for IBD**.

## Which peptides have the strongest IBD evidence, ranked?

The four candidates below are ranked by the strength of their gut-specific evidence, not by hype. BPC-157 leads because it was literally discovered in the gut and has the deepest colitis record; KPV follows on independently replicated murine colitis data; thymosin alpha-1 has a human-safety pedigree earned elsewhere; and larazotide, despite the best overall trial record, ranks last for IBD because it was never tested for IBD efficacy and failed its Phase 3 in celiac disease.

  Peptides studied for IBD — evidence at a glance

    PeptideBest IBD-specific evidenceHuman IBD trial?Grade

    BPC-157Extensive rodent GI/colitis data; one unpublished Phase 2 UC trialNo published RCTC
    KPVRobust, replicated rodent colitis; strong PepT1 mechanismNoC
    Thymosin alpha-1Preclinical colitis + old human in-vitro IBD immune dataNo IBD RCTC
    Larazotide acetateMechanistic/preclinical for IBD; Grade B in celiac but Phase 3 failedNo IBD efficacy trialC–D

BPC-157 ("Body Protection Compound-157," PL 14736) is a synthetic 15-amino-acid fragment of a protein in human gastric juice. In rodents it heals cysteamine- and TNBS-induced colitis, colocutaneous and ileoileal fistulae, anastomoses and NSAID-induced intestinal lesions.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3)[4](https://peptidevox.com/#r4) Croatian developer Pliva advanced it into a Phase 2 ulcerative-colitis trial in the early 2000s, but those results were never published, and there is no completed, published, controlled human IBD trial.[2](https://peptidevox.com/#r2) KPV (Lys-Pro-Val), the C-terminal tripeptide of α-MSH, is shuttled into inflamed epithelial cells by the PepT1 transporter — up-regulated specifically in inflamed IBD colon — where it blocks NF-κB and lowers cytokines; oral KPV attenuated both DSS- and TNBS-induced colitis in mice, and it reduced colitis-associated tumor burden in an AOM/DSS model in a PepT1-dependent way.[7](https://peptidevox.com/#r7)[9](https://peptidevox.com/#r9) But KPV has never been tested in any human clinical trial.[7](https://peptidevox.com/#r7)

Thymosin alpha-1 (thymalfasin; brand Zadaxin) is the only candidate that is an approved drug somewhere — licensed for chronic hepatitis B/C and as a cancer immunoadjuvant in more than 30 countries — giving it a human-safety pedigree the others lack.[14](https://peptidevox.com/#r14) For IBD, however, the evidence is preclinical colitis data plus a thin slice of 1980-era human in-vitro work in Crohn's and UC patients.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13) A useful cautionary note: its largest definitive human trial, the 1,089-patient TESTS sepsis RCT, was negative — promising immunomodulation does not guarantee clinical benefit.[16](https://peptidevox.com/#r16) Larazotide (AT-1001) is the most clinically advanced gut peptide ever developed, with at least four placebo-controlled celiac RCTs, yet it was never tested for efficacy in Crohn's or UC, it failed the objective permeability endpoint even in celiac, and its pivotal Phase 3 (CeDLara, [NCT03569007](https://clinicaltrials.gov/study/NCT03569007)) was discontinued for futility in June 2022.[19](https://peptidevox.com/#r19)[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)

## What does the evidence NOT support, and what should you actually rely on?

Several popular claims fail on the evidence. "BPC-157 cures Crohn's or colitis" is false as stated — there is no published human IBD trial, and the early-2000s PL 14736 study was never published.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) "KPV is a proven gut anti-inflammatory in people" is unsupported — KPV has zero human trials for any indication.[7](https://peptidevox.com/#r7) "Larazotide fixes leaky gut and therefore IBD" is not demonstrated — it failed its objective permeability endpoint and its pivotal Phase 3 in celiac, and was never tested for IBD efficacy.[20](https://peptidevox.com/#r20) And "thymosin alpha-1 treats IBD" is overstated — its real human RCTs are for hepatitis B and sepsis (the latter negative), with none for IBD.[16](https://peptidevox.com/#r16) A related trap: the GLP-2 analog teduglutide (Gattex) is FDA-approved for short bowel syndrome, a surgical complication of Crohn's — not for treating IBD inflammation itself. Do not conflate it with a colitis therapy.

What the standard of care actually is
Anti-TNFs (infliximab, adalimumab), anti-integrin vedolizumab, IL-12/23 and IL-23 inhibitors (ustekinumab, risankizumab, guselkumab), JAK inhibitors (upadacitinib, tofacitinib) and S1P modulators (ozanimod, etrasimod) are all guideline-endorsed with Grade-A human evidence.[25](https://peptidevox.com/#r25)[26](https://peptidevox.com/#r26) Peptides are, at most, experimental adjuncts under investigation — not replacements.

## What are the doses, safety concerns and legal status in 2026?

Doses are reported strictly as information, never as guidance. In animal colitis work BPC-157 doses in µg/kg–ng/kg ranges; anecdotal human use for gut indications is reported around 250–500 µg/day oral or subcutaneous — extrapolations, not validated regimens.[1](https://peptidevox.com/#r1) Mouse KPV work uses ~100 µM oral or ~16 µg/kg/day; grey-market human "use" describes 200–500 µg/day capsules with no human trial behind it.[7](https://peptidevox.com/#r7)[11](https://peptidevox.com/#r11) Thymosin alpha-1's approved hepatitis regimen is 1.6 mg subcutaneous twice weekly, with no IBD-specific dose.[14](https://peptidevox.com/#r14) Larazotide's celiac dose was 0.5 mg orally three times daily before meals — notably, higher doses were not better.[19](https://peptidevox.com/#r19)

Safety is dominated by IBD-specific concerns. BPC-157 is pro-angiogenic via VEGFR2/EGR-1, and IBD raises colorectal-cancer risk — chronic angiogenesis in a dysplasia-prone colon is an unstudied, plausible hazard warranting caution.[1](https://peptidevox.com/#r1) Thymosin alpha-1 augments Th1/CD8 and dendritic-cell activity and is a relative contraindication in deliberate immunosuppression, overlapping with IBD patients on immunosuppressants.[14](https://peptidevox.com/#r14) KPV appears benign in animals and even reduced tumor burden in the colitis-cancer model, but has no human safety profile.[9](https://peptidevox.com/#r9) Across all four, grey-market "research chemical" peptides carry documented endotoxin, heavy-metal and mislabeling risks — especially dangerous in immunosuppressed patients.[32](https://peptidevox.com/#r32)

Legally, none of these four is an FDA-approved drug for IBD. BPC-157 and KPV were on the 503A Category 2 compounding list, removed in April 2026 after nominations were withdrawn — a transitional grey zone, not an authorization — and are slated for PCAC review on July 23, 2026; removal from Category 2 does not make them legal to compound.[27](https://peptidevox.com/#r27)[28](https://peptidevox.com/#r28) Thymosin alpha-1 holds four orphan designations (none approved) and was removed from Category 2 in 2024, pending PCAC.[29](https://peptidevox.com/#r29) Larazotide is unapproved everywhere, sold only as research-use-only.[24](https://peptidevox.com/#r24) For anti-doping, BPC-157 is prohibited at all times under S0, and KPV, larazotide and thymosin alpha-1 fall under S0 as non-approved substances.[30](https://peptidevox.com/#r30)[31](https://peptidevox.com/#r31)

**Bottom line.** The idea behind these peptides — repair the epithelial barrier, calm NF-κB-driven inflammation, restore immune tolerance — is mechanistically sound and addresses upstream drivers. But for IBD they remain unproven, Grade C at best, with real legal, purity and safety unknowns. IBD must be managed by a board-certified gastroenterologist with objective monitoring; do not alter prescribed therapy to use any peptide. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome was pending at the time of writing and should be re-verified afterward.

---
Source: https://peptidevox.com/immune-gut-longevity/peptides-for-ibd
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt